Systemic sclerosis: a rare presentation
Abstract
Keywords
Full Text:
PDFReferences
Ingegnoli F, Ughi N, Mihai C. Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol. 2018;32(2):223–40.
Sticherling M. Systemic sclerosis – the dermatological perspective. J Ger Soc Dermatol. 2019;17(7):716–28.
Kucharz EJ, Kopeć-Mȩdrek M. Systemic sclerosis sine scleroderma. Adv Clin Exp Med. 2017;26(5):875–80.
Denton CP, Khanna D. Systemic sclerosis. Lancet [Internet]. 2017;390(10103):1685–99.
Schinke S, Riemekasten G. Systemic sclerosis. Internist. 2019;60(12):1251–69.
Van den Hombergh WMT, Carreira PE, Knaapen-Hans HKA, van den Hoogen FHJ, Fransen J, Vonk MC. An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first
symptoms and auto-antibodies: Derivation and validation. Rheumatol. 2016;55(11):2023–32.
Johnson SR. New ACR EULAR guidelines for systemic sclerosis classification. Curr Rheumatol Rep. 2015;17(5):1–8.
Sobolewski P, Maślińska M, Wieczorek M, Łagun Z, Malewska A, Roszkiewicz M, et al. Systemic sclerosis - Multidisciplinary disease: Clinical features and treatment. Reumatologia. 2019;57(4):221–33.
Pearson DR, Werth VP, Pappas-Taffer L. Systemic sclerosis: Current concepts of skin and systemic manifestations. Clin Dermatol. 2018;36(4):459–74.
Horner KL, Raugi GJ, Wemple MA. CREST syndrome. eMedicine Dermatology. 2008; Available at: http://www.emedicine.medscape. com. Accessed on 20 March 2020.
Tangri N, Young BM. Soft-tissue infection and underlying calcinosis of CREST syndrome. Canad Medic Assoc J. 2006;175(9):1060–1.
Herrick AL. Review: Pathogenesis of Raynaud’s phenomenon. Rheumatology. 2005;44:587–96.
Sunderkotter C, Riemekasten G. Pathophysiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology. 2006;45:iii33.
Sheehan NJ. Dysphagia and other manifestations of oesophageal involvement in the musculoskeletal diseases. Rheumatology. 2008;47(6):746–52.
Pitrez EH, Bredemeier M, Xavier RM, Capobianco KG, Restelli VG, Vieira MV, et al. Oesophageal dysmotility in systemic sclerosis: comparison of HRCT and scintigraphy. Br J Radiol. 2006;79:719–24.
Jones J, Brenner C, Chinn R, Bunjer CB. Pictorial review: Radiological associations with dermatological disease. Br J Radiol. 2005;78:662–71.
Hu PQ, Fertig N, Medsger TA, Wright TM. Molecular Recognition Patterns of Serum Anti-DNA Topoisomerase I Antibody in Systemic Sclerosis. J Immunol. 2004;173(4):2834–41.
Lt. John Scott Donoughe, DO, MPAS, PA-C. Scleroderma: Quick Recertification Series. 2018;(10):53-4.
Wigley FM, Korn JH, Csuka ME, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998;41(4):670-7.